Search
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigational[L64097] It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activators of transcription (STATs) that regulate immune cell function. … [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]
Ammonium chloride
go.drugbank.com/drugs/DB06767ApprovedInvestigationalVet approvedAmmonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.
Mixtures: OB COMBI BATUK PILEK, PECODE ŞURUP, 150 GLevobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnLevobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. … In general, the majority of potential adverse effects are predominantly associated with inappropriate administration methods that may cause systemic exposure and/or toxicity associated with overexposure
Products: CHIROCAINE 5.0 MG/ML, CHIROCAINE INJECTION 5 mg/mlPiretanide
go.drugbank.com/drugs/DB02925Approvedan aromatic nucleus in the presence of other aromatically bonded functional groups. … Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in
Categories: combinations of sulfonamidesDexchlorpheniramine maleate
go.drugbank.com/drugs/DB09555ApprovedDexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine.
Products: SOMIN TAB 2 mg, POLARAX TABLET 2 mgZilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigational[A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis. … [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.
Products: Zılbrysq 16,6 mg/0,416 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet), Zılbrysq 23 mg/0,574 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet)Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalof life. … Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.
Products: TAGRISSO® 40 MG, TAGRISSO® 80 MG.Thiethylperazine
go.drugbank.com/drugs/DB00372ApprovedInvestigationalWithdrawnThis piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigational[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. … However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.
Products: Erigib 150 mg Sert Kapsül, 28 ADET, ERIVEDGE 150 MG SERT KAPSÜL ,28 KAPSÜLEtafedrine
go.drugbank.com/drugs/DB11587ApprovedThe hydrochloride is be prepared by passing hydrogen chloride through a solution of ethylephedrine in diethyl ether [F6]. This belongs to the family of medications called _decongestants_. … Etafedrine (INN) or ethylephedrine is a long-acting bronchodilator and has been an ingredient combined with other drugs in the brand names Nethaprin [A32757] and Dalmacol [L2568].